Repair of cartilage defects associated with injury or pathology is a clinically relevant problem. Chondral tissue, especially articular cartilages, has a poor regenerative potential. Inflammation triggers the growth of connective tissue, which cannot exert the normal function of the hyaline cartilage. This contributes to the progression of the pathology and eventually raises the need for surgery. At present, there are no pharmaceutical drugs capable of restoring the damaged cartilage. However, advances in cell-based technology hold promise for regenerative medicine. Reports describing fabrication of autologous cartilage transplants pose a special interest. A registration dossier of a biomedical cell product must contain the product’s specifications, presenting the basic characteristics of the product that can be used to assess its quality. This review looks at a few basic parameters that can be used to verify the authenticity of the cell product derived from autologous chondrocytes and describe its specifications.